{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-23-001927","form_type":"8-K","ticker":"DRMA","cik":"0001853816","company_name":"Dermata Therapeutics, Inc.","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:47.170135+00:00","generated_at":"2026-06-19T07:18:54.021007+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Dermata Therapeutics reports FY2022 cash of $6.2M; plans DMT310 Phase 3 in 2H 2023","bullets":["Cash and equivalents $6.2M at Dec 31, 2022, down from $10.8M a year earlier.","R&D expenses $5.7M in FY2022 vs $3.5M in FY2021, driven by DMT310 clinical/CMC costs.","Cash expected to fund operations into Q3 2023; no revenue reported.","End-of-Phase 2 meeting with FDA for DMT310 (acne) expected in Q2 2023; Phase 3 start in H2 2023.","DMT410 partnership discussions ongoing for topical botulinum toxin delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-23-001927","json":"https://secwatch.observer/filing/0001654954-23-001927.json","markdown":"https://secwatch.observer/filing/0001654954-23-001927.md","text":"https://secwatch.observer/filing/0001654954-23-001927.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/0001654954-23-001927-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/drma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:18:54.021007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5297414b4d49af5ce939f81e0caee934a9e72516","claim":"Dermata Therapeutics, Inc. reported financial results for the year ended December 31, 2022.","evidence_excerpt":"On February 21, 2023, Dermata Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495423001927/0001654954-23-001927-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}